AIBiotics Therapies, Inc.
corporate_fare Company Profile
AIBiotics Therapies, Inc. (OTC:AIBT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 9 items for AIBT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-20, rated 8/10. Across its 9 most recent items scored 7 or higher, the top rating is 9/10, with 8 rated 8 or above. Recent SEC coverage for AIBT spans 10-Q, 8-K, 10-K.
Recent high-impact activity:
- AIBiotics Q3 10-Q: Going Concern Reaffirmed, Material Weakness Disclosed, Share Count Tops 1 Billion
- Aibotics Closes NovaCore Labs Asset Buy; Issues 100M Shares to Two Executives
- Aibotics to Acquire Empulser Enterprises for Up to $22M in Series C Preferred Stock
- Aibotics Q2 Loss Widens; Working Capital Deficit Hits $4.9M, Shares Outstanding Surge 48%
- AIBOTICS Reports Zero Revenue, $418K Net Loss in Q1 2026
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 80,439 shares in AIBT as of the October 30, 2026 settlement, a 81.4% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 79.5% of AIBT volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.